What is Xeris Biopharma Holdings's earnings per share (EPS)?

Xeris Biopharma Holdings (XERS) reported diluted earnings per share of $0.00 for fiscal year 2025. This represents a 100.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Xeris Biopharma Holdings Financials

XERS

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Xeris Biopharma Holdings (XERS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 40/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Xeris Biopharma Holdings has an operating margin of 8.5%, meaning the company retains $9 of operating profit per $100 of revenue. This results in a moderate score of 41/100, indicating healthy but not exceptional operating efficiency. This is up from -16.6% the prior year.

Growth

100

Xeris Biopharma Holdings's revenue surged 43.7% year-over-year to $291.8M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Xeris Biopharma Holdings has elevated debt relative to equity (D/E of 16.10), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

Xeris Biopharma Holdings's current ratio of 2.19 indicates adequate short-term liquidity, earning a score of 40/100. The company can meet its near-term obligations, though with limited headroom.

Returns

Xeris Biopharma Holdings generates a 4.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 20/100.

Altman Z-Score Distress

0.62

Xeris Biopharma Holdings scores 0.62, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.0B) relative to total liabilities ($369.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Piotroski F-Score Strong

8/9

Xeris Biopharma Holdings passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

51.67x

For every $1 of reported earnings, Xeris Biopharma Holdings generates $51.67 in operating cash flow ($28.6M OCF vs $554K net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage At Risk

0.9x

Xeris Biopharma Holdings earns $0.9 in operating income for every $1 of interest expense ($24.9M vs $29.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$291.8M

YoY+43.7%

5Y CAGR+70.2%

Xeris Biopharma Holdings generated $291.8M in revenue in fiscal year 2025. This represents an increase of 43.7% from the prior year.

EBITDA

$26.2M

YoY+180.8%

Xeris Biopharma Holdings's EBITDA was $26.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 180.8% from the prior year.

Net Income

$554K

YoY+101.0%

Xeris Biopharma Holdings reported $554K in net income in fiscal year 2025. This represents an increase of 101.0% from the prior year.

EPS (Diluted)

$0.00

YoY+100.0%

Xeris Biopharma Holdings earned $0.00 per diluted share (EPS) in fiscal year 2025. This represents an increase of 100.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$111.0M

YoY+55.0%

5Y CAGR+24.2%

Xeris Biopharma Holdings held $111.0M in cash against $220.3M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

166M

YoY+11.2%

5Y CAGR+22.8%

Xeris Biopharma Holdings had 166M shares outstanding in fiscal year 2025. This represents an increase of 11.2% from the prior year.

Margins & Returns

Gross Margin

85.4%

YoY+3.5pp

5Y CAGR+31.1pp

Xeris Biopharma Holdings's gross margin was 85.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.5 percentage points from the prior year.

Operating Margin

8.5%

YoY+25.1pp

5Y CAGR+417.4pp

Xeris Biopharma Holdings's operating margin was 8.5% in fiscal year 2025, reflecting core business profitability. This is up 25.1 percentage points from the prior year.

Net Margin

0.2%

YoY+27.2pp

5Y CAGR+446.2pp

Xeris Biopharma Holdings's net profit margin was 0.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 27.2 percentage points from the prior year.

Return on Equity

4.0%

5Y CAGR+274.0pp

Xeris Biopharma Holdings's ROE was 4.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$31.2M

YoY+21.9%

5Y CAGR+8.3%

Xeris Biopharma Holdings invested $31.2M in research and development in fiscal year 2025. This represents an increase of 21.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

XERS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$291.8M+43.7%	$203.1M+23.9%	$163.9M+48.7%	$110.2M+122.3%	$49.6M+142.7%	$20.4M
Cost of Revenue	$42.6M+15.6%	$36.8M+28.6%	$28.6M+26.6%	$22.6M+70.0%	$13.3M+42.8%	$9.3M
Gross Profit	$249.3M+50.0%	$166.2M+22.9%	$135.3M+54.4%	$87.6M+141.5%	$36.3M+226.6%	$11.1M
R&D Expenses	$31.2M+21.9%	$25.6M+14.4%	$22.3M+6.6%	$21.0M-16.7%	$25.2M+20.3%	$20.9M
SG&A Expenses	$182.4M+11.6%	$163.5M+11.9%	$146.1M+6.1%	$137.7M+9.6%	$125.7M+70.5%	$73.7M
Operating Income	$24.9M+174.0%	-$33.6M+23.5%	-$44.0M+46.3%	-$81.9M+28.8%	-$115.2M-37.8%	-$83.5M
Interest Expense	$29.1M-4.6%	$30.5M+14.6%	$26.6M+88.7%	$14.1M+96.4%	$7.2M-32.6%	$10.7M
Income Tax	$0+100.0%	-$2.3M-81.6%	-$1.2M+12.3%	-$1.4M	$0+100.0%	-$110K
Net Income	$554K+101.0%	-$54.8M+11.9%	-$62.3M+34.2%	-$94.7M+22.9%	-$122.7M-34.7%	-$91.1M
EPS (Diluted)	$0.00+100.0%	$-0.37+17.8%	$-0.45+35.7%	$-0.70+54.8%	$-1.55	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$85.8M+15.4%	$74.4M+4.0%	$71.5M+19.0%	$60.1M0.0%	$60.1M+10.7%	$54.3M+12.9%	$48.1M+18.3%	$40.6M
Cost of Revenue	$10.9M-0.4%	$11.0M-7.6%	$11.9M+36.3%	$8.7M-7.9%	$9.5M-30.3%	$13.6M+74.5%	$7.8M+30.5%	$6.0M
Gross Profit	$74.9M+18.1%	$63.4M+6.3%	$59.6M+16.1%	$51.4M+1.5%	$50.6M+24.5%	$40.7M+1.0%	$40.3M+16.2%	$34.7M
R&D Expenses	$7.9M+5.2%	$7.5M-7.1%	$8.1M+3.9%	$7.8M+27.3%	$6.1M+3.5%	$5.9M+2.2%	$5.8M-26.4%	$7.8M
SG&A Expenses	$47.5M+2.2%	$46.5M+4.7%	$44.4M+0.9%	$44.0M+9.7%	$40.1M-10.7%	$45.0M+12.4%	$40.0M+4.2%	$38.4M
Operating Income	$16.8M+149.2%	$6.7M+50.2%	$4.5M+245.0%	-$3.1M-284.0%	$1.7M+113.0%	-$12.9M-57.5%	-$8.2M+42.5%	-$14.2M
Interest Expense	$7.2M-1.6%	$7.3M-1.2%	$7.4M+0.7%	$7.3M-5.2%	$7.7M-1.1%	$7.8M-2.2%	$8.0M+13.3%	$7.0M
Income Tax	$0	$0	$0	$0	$0+100.0%	-$3.3M-543.8%	$749K+144.0%	$307K
Net Income	$11.1M+1684.4%	$621K+132.2%	-$1.9M+79.1%	-$9.2M-80.3%	-$5.1M+67.5%	-$15.7M-4.9%	-$15.0M+20.9%	-$19.0M
EPS (Diluted)	N/A	$0.00+100.0%	$-0.01+83.3%	$-0.06	N/A	$-0.11-10.0%	$-0.10+28.6%	$-0.14

XERS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$383.5M+18.7%	$323.1M+0.1%	$322.6M-6.4%	$344.5M+13.2%	$304.4M+91.2%	$159.2M
Current Assets	$240.3M+43.3%	$167.7M+7.3%	$156.3M-16.4%	$186.8M+31.0%	$142.6M-6.3%	$152.2M
Cash & Equivalents	$111.0M+55.0%	$71.6M+6.2%	$67.4M-44.7%	$122.0M+81.3%	$67.3M+78.9%	$37.6M
Inventory	$68.7M+42.5%	$48.2M+24.0%	$38.8M+57.0%	$24.7M+36.5%	$18.1M+116.9%	$8.4M
Accounts Receivable	$51.0M+26.3%	$40.4M+3.1%	$39.2M+27.1%	$30.8M+76.6%	$17.5M+153.9%	$6.9M
Goodwill	$22.9M0.0%	$22.9M0.0%	$22.9M0.0%	$22.9M0.0%	$22.9M	$0
Total Liabilities	$369.8M+4.9%	$352.7M+7.1%	$329.4M+10.0%	$299.3M+43.1%	$209.1M+66.8%	$125.4M
Current Liabilities	$109.6M+9.1%	$100.4M+5.5%	$95.2M+29.3%	$73.6M-6.9%	$79.0M+180.2%	$28.2M
Long-Term Debt	$220.3M+1.5%	$217.0M+13.7%	$190.9M+2.1%	$187.1M+112.4%	$88.1M+1.2%	$87.0M
Total Equity	$13.7M+146.2%	-$29.6M-336.7%	-$6.8M-115.0%	$45.2M-52.6%	$95.2M+182.1%	$33.8M
Retained Earnings	-$671.3M+0.1%	-$671.9M-8.9%	-$617.0M-11.2%	-$554.8M-20.6%	-$460.1M-36.4%	-$337.4M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$383.5M+3.6%	$370.2M+10.6%	$334.7M+6.1%	$315.5M-2.4%	$323.1M+0.6%	$321.1M-3.2%	$331.7M-1.5%	$336.6M
Current Assets	$240.3M+7.3%	$224.0M+20.7%	$185.6M+13.5%	$163.5M-2.5%	$167.7M+3.0%	$162.8M-4.4%	$170.3M-1.7%	$173.3M
Cash & Equivalents	$111.0M+21.2%	$91.6M+54.5%	$59.3M+1.4%	$58.4M-18.4%	$71.6M+20.9%	$59.2M+2.8%	$57.6M-8.1%	$62.7M
Inventory	$68.7M+1.8%	$67.5M+0.3%	$67.3M+27.7%	$52.7M+9.4%	$48.2M+6.8%	$45.1M+5.0%	$43.0M+5.1%	$40.9M
Accounts Receivable	$51.0M-5.0%	$53.8M+1.3%	$53.0M+14.5%	$46.3M+14.6%	$40.4M-1.8%	$41.1M-3.1%	$42.4M+13.4%	$37.4M
Goodwill	$22.9M0.0%	$22.9M0.0%	$22.9M0.0%	$22.9M0.0%	$22.9M0.0%	$22.9M0.0%	$22.9M0.0%	$22.9M
Total Liabilities	$369.8M-0.3%	$371.1M+4.8%	$354.0M+1.0%	$350.6M-0.6%	$352.7M+0.9%	$349.4M-0.5%	$351.0M+1.5%	$345.8M
Current Liabilities	$109.6M-5.7%	$116.2M+22.1%	$95.2M+0.1%	$95.1M-5.3%	$100.4M+10.4%	$91.0M+20.6%	$75.5M+3.3%	$73.1M
Long-Term Debt	$220.3M+0.4%	$219.5M+0.4%	$218.6M+0.4%	$217.8M+0.4%	$217.0M+0.4%	$216.2M-6.2%	$230.5M+0.4%	$229.7M
Total Equity	$13.7M+1689.9%	-$861K+95.5%	-$19.3M+45.0%	-$35.1M-18.6%	-$29.6M-4.6%	-$28.3M-46.9%	-$19.3M-110.1%	-$9.2M
Retained Earnings	-$671.3M+1.6%	-$682.4M+0.1%	-$683.0M-0.3%	-$681.1M-1.4%	-$671.9M-0.8%	-$666.7M-2.4%	-$651.0M-2.4%	-$636.0M

XERS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$28.6M+177.4%	-$37.0M+21.4%	-$47.0M+54.3%	-$102.9M-7.7%	-$95.5M-18.6%	-$80.6M
Capital Expenditures	N/A	N/A	N/A	N/A	$1.1M+187.8%	$377K
Free Cash Flow	N/A	N/A	N/A	N/A	-$96.6M-19.4%	-$80.9M
Investing Cash Flow	-$696K-114.3%	$4.9M+181.3%	-$6.0M-117.4%	$34.5M-64.8%	$98.0M+457.5%	-$27.4M
Financing Cash Flow	$11.4M-68.5%	$36.2M+2342.3%	-$1.6M-101.3%	$127.5M+367.8%	$27.2M-78.4%	$126.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$20.0M+8.7%	$18.4M+10027.5%	$182K+101.8%	-$10.0M-607.9%	$2.0M+123.8%	-$8.3M+19.7%	-$10.3M+49.0%	-$20.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$333K-369.0%	-$71K+74.6%	-$279K-2046.2%	-$13K-100.1%	$10.0M+1.0%	$9.9M+115.4%	$4.6M+123.4%	-$19.6M
Financing Cash Flow	-$266K-101.9%	$13.8M+1370.3%	$942K+130.0%	-$3.1M-888.2%	$398K+579.5%	-$83K-112.6%	$659K-98.1%	$35.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

XERS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	85.4%+3.5pp	81.9%-0.7pp	82.5%+3.1pp	79.5%+6.3pp	73.1%+18.8pp	54.4%
Operating Margin	8.5%+25.1pp	-16.6%+10.3pp	-26.9%+47.5pp	-74.3%+157.9pp	-232.2%+176.6pp	-408.8%
Net Margin	0.2%+27.2pp	-27.0%+11.0pp	-38.0%+47.9pp	-85.9%+161.6pp	-247.5%+198.5pp	-446.0%
Return on Equity	4.0%	N/A	N/A	-209.5%-80.6pp	-128.9%+141.1pp	-270.0%
Return on Assets	0.1%+17.1pp	-17.0%+2.3pp	-19.3%+8.2pp	-27.5%+12.8pp	-40.3%+16.9pp	-57.3%
Current Ratio	2.19+0.5	1.67+0.0	1.64-0.9	2.54+0.7	1.80-3.6	5.40
Debt-to-Equity	16.10+23.4	-7.33+20.8	-28.15-32.3	4.14+3.2	0.92-1.7	2.58
FCF Margin	N/A	N/A	N/A	N/A	-194.8%+201.2pp	-396.1%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	87.2%+2.0pp	85.2%+1.8pp	83.4%-2.1pp	85.5%+1.2pp	84.2%+9.3pp	75.0%-8.8pp	83.8%-1.5pp	85.3%
Operating Margin	19.6%+10.5pp	9.0%+2.8pp	6.3%+11.4pp	-5.1%-7.9pp	2.8%+26.6pp	-23.8%-6.7pp	-17.0%+18.0pp	-35.0%
Net Margin	12.9%+12.1pp	0.8%+3.5pp	-2.7%+12.6pp	-15.3%-6.8pp	-8.5%+20.5pp	-29.0%+2.2pp	-31.2%+15.5pp	-46.7%
Return on Equity	81.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	2.9%+2.7pp	0.2%+0.8pp	-0.6%+2.3pp	-2.9%-1.3pp	-1.6%+3.3pp	-4.9%-0.4pp	-4.5%+1.1pp	-5.6%
Current Ratio	2.19+0.3	1.93-0.0	1.95+0.2	1.72+0.1	1.67-0.1	1.79-0.5	2.26-0.1	2.37
Debt-to-Equity	16.10+271.0	-254.90-243.6	-11.33-5.1	-6.20+1.1	-7.33+0.3	-7.63+4.3	-11.95+13.1	-25.02
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Amylyx Pharmaceuticals AMLX

$1.6B

Intellia Therape NTLA

$1.6B

Tourmaline Bio TRML

$1.2B

Dianthus Therapeutics Inc DNTH

$4.5B

Precigen Inc PGEN

$1.4B

Frequently Asked Questions

What is Xeris Biopharma Holdings's annual revenue?

Xeris Biopharma Holdings (XERS) reported $291.8M in total revenue for fiscal year 2025. This represents a 43.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Xeris Biopharma Holdings's revenue growing?

Xeris Biopharma Holdings (XERS) revenue grew by 43.7% year-over-year, from $203.1M to $291.8M in fiscal year 2025.

Is Xeris Biopharma Holdings profitable?

Yes, Xeris Biopharma Holdings (XERS) reported a net income of $554K in fiscal year 2025, with a net profit margin of 0.2%.

What is Xeris Biopharma Holdings's EBITDA?

Xeris Biopharma Holdings (XERS) had EBITDA of $26.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Xeris Biopharma Holdings have?

As of fiscal year 2025, Xeris Biopharma Holdings (XERS) had $111.0M in cash and equivalents against $220.3M in long-term debt.

What is Xeris Biopharma Holdings's gross margin?

Xeris Biopharma Holdings (XERS) had a gross margin of 85.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Xeris Biopharma Holdings's operating margin?

Xeris Biopharma Holdings (XERS) had an operating margin of 8.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Xeris Biopharma Holdings's net profit margin?

Xeris Biopharma Holdings (XERS) had a net profit margin of 0.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Xeris Biopharma Holdings's return on equity (ROE)?

Xeris Biopharma Holdings (XERS) has a return on equity of 4.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Xeris Biopharma Holdings's operating cash flow?

Xeris Biopharma Holdings (XERS) generated $28.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Xeris Biopharma Holdings's total assets?

Xeris Biopharma Holdings (XERS) had $383.5M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Xeris Biopharma Holdings spend on research and development?

Xeris Biopharma Holdings (XERS) invested $31.2M in research and development during fiscal year 2025.

How many shares does Xeris Biopharma Holdings have outstanding?

Xeris Biopharma Holdings (XERS) had 166M shares outstanding as of fiscal year 2025.

What is Xeris Biopharma Holdings's current ratio?

Xeris Biopharma Holdings (XERS) had a current ratio of 2.19 as of fiscal year 2025, which is generally considered healthy.

What is Xeris Biopharma Holdings's debt-to-equity ratio?

Xeris Biopharma Holdings (XERS) had a debt-to-equity ratio of 16.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Xeris Biopharma Holdings's return on assets (ROA)?

Xeris Biopharma Holdings (XERS) had a return on assets of 0.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Xeris Biopharma Holdings's Altman Z-Score?

Xeris Biopharma Holdings (XERS) has an Altman Z-Score of 0.62, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Xeris Biopharma Holdings's Piotroski F-Score?

Xeris Biopharma Holdings (XERS) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Xeris Biopharma Holdings's earnings high quality?

Xeris Biopharma Holdings (XERS) has an earnings quality ratio of 51.67x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Xeris Biopharma Holdings cover its interest payments?

Xeris Biopharma Holdings (XERS) has an interest coverage ratio of 0.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Xeris Biopharma Holdings?

Xeris Biopharma Holdings (XERS) scores 40 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.